Spots Global Cancer Trial Database for siltuximab
Every month we try and update this database with for siltuximab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome | NCT01513317 | Myelodysplastic... | Siltuximab Placebo Best supportive... | 18 Years - | Janssen Research & Development, LLC | |
| Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma | NCT05665725 | Non-Hodgkin Lym... | Biospecimen Col... Computed Tomogr... Positron Emissi... Siltuximab | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | NCT01266811 | Multiple Myelom... | Placebo, Velcad... Siltuximab, Vel... | 18 Years - | Centocor, Inc. | |
| A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma | NCT01484275 | High-risk Smold... | Siltuximab Placebo | 18 Years - | Janssen Research & Development, LLC | |
| A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma | NCT00401843 | Multiple Myelom... | Siltuximab Bortezomib Placebo Dexamethasone | 18 Years - 99 Years | Janssen Research & Development, LLC | |
| A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease | NCT01024036 | Multicentric Ca... | Siltuximab Placebo Best Supportive... | 18 Years - | Janssen Research & Development, LLC | |
| Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis | NCT02805868 | Myelofibrosis Polycythemia Ve... Primary Myelofi... Thrombocytopeni... | Bone Marrow Asp... Laboratory Biom... Siltuximab | 18 Years - | Northwestern University | |
| Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis | NCT03315026 | Multiple Myelom... AL Amyloidosis | Siltuximab The M.D. Anders... | 60 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma | NCT01219010 | Monoclonal Gamm... Multiple Myelom... Plasma Cell Neo... | Siltuximab | 18 Years - | Janssen Research & Development, LLC | |
| A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma | NCT00401843 | Multiple Myelom... | Siltuximab Bortezomib Placebo Dexamethasone | 18 Years - 99 Years | Janssen Research & Development, LLC | |
| A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma | NCT01309412 | Multiple Myelom... | Siltuximab | 20 Years - | Janssen Pharmaceutical K.K. | |
| A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma | NCT01484275 | High-risk Smold... | Siltuximab Placebo | 18 Years - | Janssen Research & Development, LLC | |
| An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma | NCT00402181 | Multiple Myelom... | Siltuximab Dexamethasone | 18 Years - | Centocor, Inc. | |
| Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer | NCT04191421 | Metastatic Panc... Stage IV Pancre... | Siltuximab Spartalizumab | 18 Years - | Emory University | |
| A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome | NCT01513317 | Myelodysplastic... | Siltuximab Placebo Best supportive... | 18 Years - | Janssen Research & Development, LLC | |
| Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM | NCT06352866 | Multiple Myelom... Cytokine Releas... Refractory Mult... Immune Effector... | Siltuximab Teclistamab(FDA... | 18 Years - | Case Comprehensive Cancer Center | |
| An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma | NCT00402181 | Multiple Myelom... | Siltuximab Dexamethasone | 18 Years - | Centocor, Inc. | |
| Screening Trial for Pain Relief in Schwannomatosis (STARFISH) | NCT05684692 | Schwannomatosis Schwannomas Pain, Chronic | Siltuximab Erenumab-Aooe Siltuximab Matc... Erenumab-Aooe M... | 18 Years - | Massachusetts General Hospital | |
| Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) | NCT01531998 | Myeloma | Lenalidomide Bortezomib Siltuximab Dexamethasone Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease | NCT01024036 | Multicentric Ca... | Siltuximab Placebo Best Supportive... | 18 Years - | Janssen Research & Development, LLC | |
| A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) | NCT00385827 | Cancer, Prostat... | Mitoxantrone Siltuximab Prednisone | 18 Years - | Centocor, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
